Trial intelligence / Profile preview

Asciminib in pediatric Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase

jRCT2031260265Recruiting

Sponsor
Novartis
Start
Jul 2026
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01

Overview

Open-label, single-arm trial of asciminib in chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: Major molecular response at Week 48. Started Jul 2026; status: recruiting.

02

Drugs

asciminib
03

Conditions

chronic myelogenous leukemia (CML)

Beyond the preview

Go deeper on jRCT2031260265.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on jRCT2031260265.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call